Nationwide treatment and outcomes of intrahepatic cholangiocarcinoma
HPB · 2023
DOI: 10.1016/j.hpb.2023.06.019 ↗Kurz gefasst
Fachartikel in der Zeitschrift HPB, 2023. Verfasst von Pim B Olthof und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Department of Surgery, University Medical Center Groningen, Groningen…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Hepatectomy. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Most data on the treatment and outcomes of intrahepatic cholangiocarcinoma (iCCA) derives from expert centers. This study aimed to investigate the treatment and outcomes of all patients diagnosed with iCCA in a nationwide cohort. METHODS: Data on all patients diagnosed with iCCA between 2010 and 2018 were obtained from the Netherlands Cancer Registry. RESULTS: In total, 1747 patients diagnosed with iCCA were included. Resection was performed in 292 patients (17%), 548 patients (31%) underwent palliative systemic treatment, and 867 patients (50%) best supportive care (BSC). The OS median and 1-, and 3-year OS were after resection: 37.5 months (31.0-44.0), 79.2%, and 51.6%,; with systemic therapy, 10.0 months (9.2-10.8), 38.4%, and 5.1%, and with BSC 2.2 months (2.0-2.5), 10.4%, and 1.3% respectively. The resection rate for patients who first presented in academic centers was 33% (96/292) compared to 13% (195/1454) in non-academic centers (P < 0.001). DISCUSSION: Half of almost 1750 patients with iCCA over an 8 year period did not receive any treatment with a 1-year OS of 10.4%. Three-year survival was about 50% after resection, while long-term survival was rare after palliative treatment. The resection rate was higher in academic centers compared to non-academic centers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands. Electronic address: p.olthof@erasmusmc.nl.
- Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
- Department of Research, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands.
- Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands.
- Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands.
- Department of Gastroenterology, Erasmus Medical Center, Rotterdam, the Netherlands.
Zitieren
APA
Olthof, P. B., Franssen, S., van Keulen, A. M., van der Geest, L. G., Hoogwater, F. J. H., Coenraad, M., van Driel, L. M. J. W., Erdmann, J. I., Mohammad, N. H., Heij, L., Klümpen, H. J., Tjwa, E., Valkenburg-van Iersel, L., Verheij, J., Groot Koerkamp, B., & Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG) (2023). Nationwide treatment and outcomes of intrahepatic cholangiocarcinoma. HPB. https://doi.org/10.1016/j.hpb.2023.06.019
Vancouver
Olthof PB, Franssen S, van Keulen AM, van der Geest LG, Hoogwater FJH, Coenraad M, et al. Nationwide treatment and outcomes of intrahepatic cholangiocarcinoma. HPB. 2023. doi:10.1016/j.hpb.2023.06.019
BibTeX
@article{Olthof2023,
author = {Olthof, Pim B and Franssen, Stijn and van Keulen, Anne-Marleen and van der Geest, Lydia G and Hoogwater, Frederik J H and Coenraad, Minneke and van Driel, Lydi M J W and Erdmann, Joris I and Mohammad, Nadia H and Heij, Lara and Klümpen, Heinz-Josef and Tjwa, Eric and Valkenburg-van Iersel, Liselot and Verheij, Joanne and Groot Koerkamp, Bas and Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG), Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG)},
title = {Nationwide treatment and outcomes of intrahepatic cholangiocarcinoma},
journal = {HPB},
year = {2023},
doi = {10.1016/j.hpb.2023.06.019}
}
EUVIMED